Illumina, Inc.
Illumina Completes GRAIL Spin-Off
Summary
On June 24, 2024, Illumina, Inc. completed the previously announced spin-off of GRAIL, Inc. to its shareholders. Illumina shareholders received one share of GRAIL for every six shares of Illumina, with Illumina retaining a 14.5% stake in GRAIL. GRAIL began trading under the ticker symbol 'GRAL' on June 25, 2024. The spin-off involved several agreements, including a Separation and Distribution Agreement, a Tax Matters Agreement, and an Employee Matters Agreement. Further financial and strategic details will be provided in a future investor update.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (6)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement